N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=116 Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase
Anhedonia
Primary: Change in Snaith-Hamilton Pleasure Scale Score Over Time — 37.67; 36.96; 29.62; 29.76 score on a scale — p=0.724
Phase 3 N=72 Postoperative Consequences of Intraoperative NOL Titration
Anesthesia; Adverse Effect
Primary: Pain Scores at 10-minute Intervals for the Initial Hour of Recovery — 0; 0; 1.0; 5.0 score on a scale — p=0.895
N/A N=104 Improving Asthma Care Together (IMPACT): A Shared Management Pilot Study
Asthma in Children
Primary: Asthma Responsibility Questionnaire Change From Baseline to 8 Weeks — 2.72; 2.72; 2.79; 2.31 score on a scale
N/A N=162 Highly Challenging Balance Program to Reduce Fall Rate in PD
Parkinson's Disease
Primary: Number of Falls Over 3 Month Period — 1.1; 1.6; 9.7 number of falls — p=<0.05
N/A N=26 Mindful Self Compassion for Combat Deployed Veterans With Moral Injury and Co-occurring PTSD-SUD
Substance Use Disorder · Post-traumatic Stress Disorder · Moral Injury
Primary: Self-Compassion Scale (SCS); Change From Baseline in Self-Compassion at Post-treatment — 0.45 score on a scale
N/A N=306 Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery
Primary Open Angle Glaucoma · Pseudoexfoliative Glaucoma · Pigmentary Dispersion Glaucoma
Primary: Unmedicated Mean Diurnal Intraocular Pressure (DIOP) at Month 12 — 16.9; 18.1 mmHg
N/A N=28 Comparison Between Two Treatments for Burning Mouth
Burning Mouth Syndrome
Primary: Painful Symptoms — 7.58; 6.92; 5.08; 5.33 score on a scale
Phase 3 N=136 Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 28.7 percentage of subjects
Phase 2 N=40 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID
N/A N=21 Intelligent Personal Assistant for Managing Depression in Homebound Older Adults
Aging · Physical Dependence
Primary: Change in Acceptability — 5.2; 5.27; 5.34 score on a scale — p=0.785
N/A N=388 Well-child Visit Video Project
Type 2 Diabetes
Primary: Percentage of Parents Who Are Aware of Infant Fruit Juice Consumption Recommendations — 19.57; 27.27 percentage of participants
Phase 2 N=30 Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients
Phase 1 N=30 A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0 Participants
N/A N=14 Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer
Breast Cancer
Primary: Utility of Percentage Change in Longitudinal (T1) and Transverse (T2) Relaxation Times From Baseline to First Cycle of Treatment in Assessment of Response to…